Biogen: Number of Employees 2010-2022 | BIIB

Interactive chart of Biogen (BIIB) annual worldwide employee count from 2010 to 2022.
  • Biogen total number of employees in 2021 was 9,610, a 5.6% increase from 2020.
  • Biogen total number of employees in 2020 was 9,100, a 22.97% increase from 2019.
  • Biogen total number of employees in 2019 was 7,400, a 5.13% decline from 2018.
  • Biogen total number of employees in 2018 was 7,800, a 6.85% increase from 2017.
Biogen Annual Number of Employees
2021 9,610
2020 9,100
2019 7,400
2018 7,800
2017 7,300
2016 7,400
2015 7,350
2014 7,550
2013 6,850
2012 5,950
2011 5,000
2010 4,850
2009 4,750
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $30.056B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $166.663B 10.14
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.600B 16.73
Biohaven Pharmaceutical Holding (BHVN) United States $10.272B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.442B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.38
Emergent Biosolutions (EBS) United States $1.534B 6.57
Myovant Sciences (MYOV) United Kingdom $1.224B 0.00
Zymeworks (ZYME) Canada $0.317B 0.00
Gelesis Holdings (GLS) United States $0.111B 0.00
Ambrx Biopharma (AMAM) United States $0.100B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00